Jax DiEugenio

Signatera MRD Assay Displays High Sensitivity, Specificity in Sarcoma

May 7th 2025

The Signatera MRD assay was associated with high levels of sensitivity and specificity in sarcomas.

T-DXd Followed by THP Improves pCR Rate in HER2+ Early Breast Cancer

May 7th 2025

Neoadjuvant T-DXd plus THP significantly improved pCR rates in HER2+ early breast cancer.

VCN-01 Plus Chemo Improves Survival in Newly Diagnosed Metastatic Pancreatic Cancer

May 7th 2025

The addition of VCN-01 to gemcitabine and nab-paclitaxel improved survival in newly diagnosed metastatic pancreatic cancer.

Dr Shum on the Evolving Treatment Paradigm for EGFR+ NSCLC

May 6th 2025

Pooled Analysis Shows POD24 Strongly Predicts Poor Survival in Newly Diagnosed MCL

May 6th 2025

Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.

First-Line Elraglusib Plus Chemo Improves Survival in Metastatic Pancreatic Cancer

May 6th 2025

The addition of elraglusib to gemcitabine and nab-paclitaxel improved overall survival is first-line metastatic pancreatic cancer.

FDA Grants Fast Track Designation to Givinostat for Polycythemia Vera

May 6th 2025

The FDA has granted fast-track designation to givinostat for the treatment of patients with polycythemia vera.

Acalabrutinib Plus BR Wins EU Approval for Previously Untreated, Transplant-Ineligible Mantle Cell Lymphoma

May 6th 2025

The European Commission has approved acalabrutinib plus bendamustine and rituximab for previously untreated, transplant-ineligible mantle cell lymphoma.

FDA Grants Fast Track Designation to BI-1808 in Select Cutaneous T-Cell Lymphoma

May 3rd 2025

BI-1808 has received FDA fast track designation for the treatment of patients with select cutaneous T-cell lymphoma subtypes.

Dr Hall on the Feasibility of ICI Continuation and Rechallenge Strategies in Second-Line Metastatic RCC

May 2nd 2025

Evan T. Hall, MD, MPhil, discusses the evolving evidence base surrounding ICI continuation and rechallenge strategies in the second-line treatment of metastatic renal cell carcinoma.

Dr Shreenivas on the FDA Approval of Penpulimab Plus Chemo for Frontline Non-Keratinizing Nasopharyngeal Carcinoma

May 2nd 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab plus chemotherapy for the frontline treatment of non-keratinizing nasopharyngeal carcinoma.

Oncology Experts Highlight Top Takeaways From the 2025 AACR Annual Meeting

May 2nd 2025

Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.

FDA Issues CRL to TLX101-CDx for Glioma Imaging

May 1st 2025

The FDA issued a complete response letter to the new drug application seeking the approval of TLX101-CDx as an imaging agent for glioma.

KN026 Plus Chemo Improves PFS in Pretreated HER2+ Gastric/GEJ Cancer

May 1st 2025

KN026 plus chemotherapy significantly improves PFS in second-line and later HER2-positive advanced gastric/GEJ cancer.

Dr Kuerer on Selective Surgery Omission After Response to Neoadjuvant Therapy in Invasive Breast Cancer

April 30th 2025

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast cancer.

Dr Randall on the Use of Osteosarcoma Spheroid Models to Streamline Preclinical Therapeutic Development

April 30th 2025

R. Lor Randall, MD, FASCO, discussed the development and application of three-dimensional spheroid models for high-throughput drug screening in osteosarcoma research.

Dr Shadman on the Utility of a Meta Analysis of BTK Inhibitors in R/R CLL

April 30th 2025

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta analysis of BTK inhibitors in relapsed/refractory CLL.

Adjuvant Trifluridine/Tipiracil Benefit is Limited to Select Subgroups in MRD+ CRC

April 30th 2025

Trifluridine/tipiracil showed a favorable safety profile and numerically improved DFS vs placebo in MRD-positive CRC.

Dr Petrylak on the Importance of Early Detection to Minimize Treatment Intensity in Testicular Cancer

April 30th 2025

Neoadjuvant Botensilimab Plus Balstilimab Is Active, Safe Regardless of Mismatch Repair Status in Solid Tumors

April 30th 2025

Botensilimab and balstilimab proved active and safe as neoadjuvant therapy in patients with mismatch repair–deficient and –proficient solid tumors.